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Summary
Background The indirect effects of pneumococcal conjugate vaccines (PCVs) are mediated through reductions in 
carriage of vaccine serotypes. Data on PCVs in Asia and the Pacific are scarce. Fiji introduced the ten-valent PCV 
(PCV10) in 2012, with a schedule consisting of three priming doses at 6, 10, and 14 weeks of age and no booster dose 
(3 + 0 schedule) without catch-up. We investigated the effects of PCV10 introduction using cross-sectional 
nasopharyngeal carriage surveys.
Methods We did four annual carriage surveys (one pre-PCV10 and three post-PCV10) in the greater Suva area in Fiji, 
during 2012–15, of 5–8-week-old infants, 12–23-month-old children, 2–6-year-old children, and their caregivers (total 
of 8109 participants). Eligible participants were of appropriate age, had axillary temperature lower than 37°C, and had 
lived in the community for at least 3 consecutive months. We used purposive quota sampling to ensure a proper 
representation of the Fiji population. Pneumococci were detected by real-time quantitative PCR, and molecular 
serotyping was done with microarray.
Findings 3 years after PCV10 introduction, vaccine-serotype carriage prevalence declined, with adjusted prevalences 
(2015 vs 2012) of 0·56 (95% CI 0·34–0·93) in 5–8-week-old infants, 0·34 (0·23–0·49) in 12–23-month-olds, 
0·47 (0·34–0·66) in 2–6-year-olds, and 0·43 (0·13–1·42) in caregivers. Reductions in PCV10 serotype carriage were 
evident in both main ethnic groups in Fiji; however, carriage of non-PCV10 serotypes increased in Indigenous Fijian 
infants and children. Density of PCV10 serotypes and non-PCV10 serotypes was lower in PCV10-vaccinated children 
aged 12–23 months than in PCV10-unvaccinated children of the same age group (PCV10 serotypes –0·56 [95% CI 
–0·98 to –0·15], p=0·0077; non-PCV10 serotypes –0·29 [–0·57 to –0·02], p=0·0334).
Interpretation Direct and indirect effects on pneumococcal carriage post-PCV10 are likely to result in reductions in 
pneumococcal disease, including in infants too young to be vaccinated. Serotype replacement in carriage in Fijian 
children, particularly Indigenous children, warrants further monitoring. Observed changes in pneumococcal density 
might be temporal rather than vaccine related.
Funding Department of Foreign Affairs and Trade of the Australian Government through the Fiji Health Sector Support 
Program; Victorian Government’s Operational Infrastructure Support Program; Bill & Melinda Gates Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Streptococcus pneumoniae (the pneumococcus) is a 
common cause of community-acquired pneumonia and 
causes an estimated 826 000 annual paediatric deaths 
worldwide.1 Variations in the pneumococcal capsule give 
rise to more than 90 different serotypes, a subset of 
which is covered by pneumococcal conjugate vaccines 
(PCVs). PCVs provide direct protection against invasive 
pneumococcal disease, pneumonia, and the carriage 
of vaccine serotypes.2 The indirect (herd) effects of 
PCVs on disease are mediated by carriage, because 
reduced carriage of vaccine serotypes in vaccinated 
children limits their transmission to other age groups.3 
Pneumococcal carriage is considered a prerequisite to 
pneumococcal disease.4 Therefore, infant immunisation 
extends protection to unvaccinated individuals and 
increases the cost-effectiveness of the vaccine.5,6 Elimi-
nation of vaccine serotypes leads to increased colonisation 
and subsequent disease due to non-vaccine serotypes, 
known as serotype replacement.7 In some settings, sero-
type replacement in disease has partly eroded the public 
health benefit provided by PCVs.8,9
Pneumococcal carriage surveys can supplement 
disease surveillance by assessing the effects of PCV 
introduction on carriage.10 Because the occurrence of 
invasive pneumococcal disease is rare, carriage surveys 
provide a practical alternative to disease surveillance in 
settings where little or no pre-PCV data on invasive 
pneumococcal disease are available. The effect of PCV on 
pneumococcal carriage varies by setting, probably 
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because of differences in pre-PCV carriage epidemiology, 
vaccine schedules, and coverage.11 Few studies have been 
done in settings where PCV10 or PCV13 was introduced 
without previous use of PCV7. Studies assessing the 
effect of PCV10 in Kenya, Brazil, and Iceland (all settings 
without previous use of PCV7) found reductions in 
PCV10 serotype carriage among vaccine-eligible children 
and, where measured, reductions in carriage among 
older, unvaccinated age groups.12–14
High pneumococcal density in the nasopharynx has 
been associated with respiratory infection and pneu-
monia in children and implicated in transmission in 
animal studies.15,16 Few data on the effect of PCVs on 
pneumococcal carriage density exist.
Because PCV10 uses Haemophilus influenzae protein D 
as a carrier protein, there has been speculation that this 
vaccine could reduce H influenzae carriage and associated 
disease. The effect of PCV10 on H influenzae carriage has 
not been clearly shown in clinical trials, and results of 
cross-sectional studies vary.12,13,17
Support from Gavi, the Vaccine Alliance, has facilitated 
PCV introduction in low-income countries, although 
uptake has lagged in the predominantly middle-income 
countries in the WHO western Pacific region.18 Fiji has 
a high incidence of paediatric pneumonia (607 per 
100 000 children younger than 5 years) and invasive 
pneumo coccal disease (26·5 per 100 000 children 
younger than 5 years), and 44% of children aged 
3–13 months carry pneumococci.19–21 Rates of pneumo-
coccal carriage and disease are higher in Indigenous 
Fijians (iTaukei) than in Fijians of Indian descent 
(FID).19–21 In October, 2012, Fiji added PCV10 to their 
Research in context
Evidence before this study
We searched PubMed for evidence of ten-valent pneumococcal 
conjugate vaccine (PCV10) effect on Streptococcus pneumoniae 
published before Sept 1, 2017, with the following terms in 
combination: “PCV10”, “Streptococcus pneumoniae”, 
“pneumococc*”, “carriage”, “colonisation”, “impact”, “effect”, 
“direct”, “indirect”, and “herd”. We identified three 
population-based studies on the effect of PCV10 on carriage in 
settings without previous use of PCV7; two of these studies 
included unvaccinated age groups. One study was done in a 
region of Kenya where PCV10 was introduced with a 
3 + 0 schedule with a catch-up campaign for children younger 
than 5 years, and included participants from ten age strata. 
A second study was from Brazil, where PCV10 was introduced by 
use of a 3 + 1 schedule with catch-up for children younger than 
23 months, and included only children aged 12–23 months. 
The third study was from Iceland, where PCV10 was introduced 
by use of a 2 + 1 schedule without catch up, and included children 
aged 1–6 years. The Kenya study reported a 64% reduction in 
carriage of PCV10 serotypes in children younger than 5 years and 
a 66% reduction in participants older than 5 years. The Brazil 
study found a 91% reduction in PCV10 serotype carriage in 
children aged 12–23 months. In Iceland, there was a 
94% reduction in carriage of PCV10 serotypes in age-eligible 
children, and a 56% reduction in older, unvaccinated children. 
The Brazil and Kenya studies investigated the effect of PCV10 on 
Haemophilus influenzae carriage, with increased carriage reported 
in Brazil and reduced carriage reported in Kenya, although the 
authors of the Kenya study questioned whether the reduction 
they observed was attributable to the vaccine.
Added value of this study
We did representative population-based annual surveys 
investigating the effect of PCV10 introduction on 
pneumococcal carriage in Fiji on four age groups, providing, 
to our knowledge, the first published data on PCV effects in the 
Pacific. 3 years after PCV10 introduction, we found reductions 
in PCV10 serotype carriage in 12–23-month-olds, older 
children, and unvaccinated 5–8-week-old infants, evidence of 
indirect effects of PCV on carriage in young, unvaccinated 
infants. There was some evidence of indirect effects of PCV10 
on carriage in caregivers. With sensitive and quantitative 
molecular methods for serotyping, we were able to investigate 
the effects of PCV10 introduction on circulating pneumococcal 
populations and on pneumococcal carriage density. We found 
no reduction in carriage of H influenzae in 12–23-month-old 
children after PCV10 introduction. We assessed the effects of 
PCV10 introduction for the two main ethnic groups in Fiji and 
found that, although PCV10 serotype carriage declined in both 
groups, serotype replacement occurred solely in the iTaukei 
population.
Implications of all the available evidence
Our study further supports the use of PCV in low-income and 
middle-income countries, including those in Asia and the 
Pacific. In addition to reducing carriage and disease caused by 
vaccine serotypes in vaccinated children, there is strong 
evidence that PCV introduction provides indirect protection. 
The implication of the observed effects on carriage is that PCV 
use could reduce pneumococcal disease in both vaccinated and 
unvaccinated age groups. Carriage studies are a valid and 
practical way to assess pneumococcal vaccine effects in settings 
where disease surveillance is difficult. Evidence suggests that 
PCV10 should not be considered a feasible strategy to reduce 
H influenzae carriage. Future research could examine how 
differences in PCV schedules, coverage, and the use of catch-up 
campaigns affect carriage in both vaccinated and unvaccinated 
age groups, to provide evidence to guide countries planning to 
introduce PCV. The speed and extent of serotype replacement 
in carriage, and the propensity for particular serotypes to 
increase after PCV introduction, varies by country and warrants 
ongoing surveillance. Future studies could assess the ability of 
models to predict serotype replacement in carriage with 
pre-PCV carriage data.
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national immunisation programme with a schedule of 
three priming doses at 6, 10, and 14 weeks of age and no 
booster dose (3 + 0 schedule). We did annual cross-
sectional nasopharyngeal carriage surveys to investigate 
the effect of PCV10 introduction on pneumococcal 
carriage by age group, year, and ethnicity. The objective 
of this study was to describe the prevalence of PCV10 and 
non-PCV10 serotypes in infants aged 5–8 weeks, children 
aged 12–23 months, children aged 2–6 years, and their 
care givers before PCV10 intro duction and during 3 years 
afterwards. We investi gated pneumococcal carriage 
density by comparing PCV10-vaccinated children aged 
12–23 months with unvaccinated children of the same 
age, hypothesising that serotype-specific immune 
responses in vaccinated children would restrict the 
ability of PCV10 serotypes to grow to high density. 
The use of sensitive mole cular methods enabled 
examination of serotype distribution, pneumococcal 
density, and serotype-specific density. We also examined 
H influenzae carriage in the 12–23-month-old group.
2012 2013 2014 2015 p value*
5–8-week-old infants
Number of participants 499 510 500 497 ··
Median age in weeks (IQR) 6·3 (5·6–7·1) 5·7 (5·3–5·9) 6·3 (6·1–6·6) 6·1 (5·6–6·6) 0·450
Sex
Girls 258 (52%) 251 (49%) 219 (44%) 248 (50%) 0·074
Boys 241 (48%) 259 (51%) 281 (56%) 249 (50%)  ··
Ethnicity
iTaukei 298 (60%) 310 (61%) 291 (58%) 303 (61%) 0·923
FID 199 (40%) 197 (39%) 207 (41%) 193 (39%) ··
Other 2 (<1%) 3 (1%) 2 (<1%) 1 (<1%) ··
Residential location
Rural 244 (49%) 259 (51%) 251 (50%) 281 (57%) 0·052
Urban or peri-urban 255 (51%) 251 (49%) 249 (50%) 216 (43%) ··
Median number of children younger than 
5 years in household (IQR)
2 (1–2) 1 (1–2) 1 (1–2) 2 (1–2) 0·882
Exposure to household cigarette smoke 203 (41%) 267 (52%) 265 (53%) 276 (56%) <0·0001
Symptoms of URTI 55 (11%) 37 (7%) 108 (22%) 111 (22%) <0·0001
Antibiotic use in previous fortnight† 12 (2%) 9 (2%) (n=509) 15 (3%) 6 (1%) 0·221
Poverty‡ 308 (69%) (n = 447) 222 (44%) 186 (37%) 278 (56%) <0·0001
Born by vaginal delivery 456 (91%) 457 (90%) 405 (81%) 424 (85%) <0·0001
Breastfeeding at time of survey 468 (94%) (n=498) 448 (88%) 472 (94%) 469 (94%) <0·0001
12–23-month-old children
Number of participants 500 505 501 498 ··
Median age in months (IQR) 16·6 (14·3–19·7) 18·3 (14·9–21·0) 17·2 (14·5–20·0) 18·2 (15·1–21·5) 0·0001
Sex
Girls 239 (48%) 231 (46%) 201 (40%) 230 (46%) 0·079
Boys 261 (52%) 274 (54%) 300 (60%) 268 (54%) ·· 
Ethnicity
iTaukei 300 (60%) 302 (60%) 291 (58%) 301 (60%) 0·134
FID 197 (39%) 203 (40%) 210 (42%) 197 (40%) ··
Other 3 (1%) 0 (0%) 0 (0%) 0 (0%) ··
Residential location
Rural 243 (49%) 255 (50%) 251 (50%) 201 (40%) 0·0035
Urban or peri-urban 257 (51%) 250 (50%) 250 (50%) 297 (60%) ··
Median number of children younger than 
5 years in household (IQR)
2 (1–2) 2 (1–2) 1 (1–2) 2 (1–3) 0·0001
Exposure to household cigarette smoke 262 (52%) 284 (56%) 303 (60%) 247 (50%) 0·0036
Symptoms of URTI 165 (33%) 175 (35%) 224 (45%) 183 (37%) 0·0006
Previously vaccinated with PCV10 0 (0%) 11 (2%) (n=504) 474 (95%) 498 (100%) <0·0001
Antibiotic use in previous fortnight† 53 (11%) 30 (6%) (n=503) 12 (2%) 28 (6%) <0·0001
Poverty‡ 341 (77%) (n=441) 307 (61%) 253 (51%) (n=500) 258 (52%) <0·0001
Breastfeeding at time of survey 187 (37%) 86 (17%) 237 (47%) 141 (28%) <0·0001
(Table 1 continues on next page)
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Methods
Study design and participants
Fiji is an upper-middle-income Pacific island nation 
with an estimated population of 884 887, composed of 
57% iTaukei and 37% FID. Approximately half of Fijians 
live in rural areas. This study was done in the greater Suva 
area. Suva is the capital and largest city in Fiji and is 
located in the central division of Viti Levu, the largest 
island in Fiji, where the majority of the population resides. 
We identified communities and health centres on the 
basis of proximity to ultra-low temperature freezers, 
because carriage samples needed to be stored within 8 h of 
collection. Recruitment occurred at the two largest health 
centres in the greater Suva area, Nausori Health Centre 
2012 2013 2014 2015 p value*
(Continued from previous page)
2–6-year-old children
Number of participants 518 516 505 513 ··
Median age in years (IQR) 3·8 (2·8–5·2) 3·8 (3·0–4·7) 4·1 (3·1–5·0) 4·1 (3·1–5·2) 0·028
Sex
Girls 250 (48%) 234 (45%) 253 (50%) 266 (52%) 0·190
Boys 268 (52%) 282 (55%) 252 (50%) 247 (48%) ··
Ethnicity
iTaukei 313 (60%) 305 (59%) 298 (59%) 303 (59%) 0·636
FID 197 (38%) 208 (40%) 203 (40%) 207 (40%) ··
Other 8 (2%) 3 (1%) 4 (1%) 3 (1%) ··
Residential location
Rural 260 (50%) 260 (50%) 249 (49%) 243 (47%) 0·759
Urban or peri-urban 258 (50%) 256 (50%) 256 (51%) 270 (53%) ··
Median number of children younger than 
5 years in household (IQR)
2 (1–2) 2 (1–2) 2 (1–2) 2 (1–2) 0·261
Exposure to household cigarette smoke 308 (59%) 296 (57%) 251 (50%) 274 (53%) 0·0090
Symptoms of URTI 203 (39%) 155 (30%) 141 (28%) 157 (31%) 0·0005
Previously vaccinated with PCV10 0 (0%) 0 (0%) 1 (<1%) 116 (23%) <0·0001
Antibiotic use in previous fortnight† 61 (12%) 27 (5%) (n=515) 9 (2%) 11 (2%) <0·0001
Poverty‡ 342 (78%) (n=437) 354 (69%) 295 (58%) 266 (52%) <0·0001
Caregivers
Number of participants 508 511 516 512 ··
Median age in years (IQR) 30·5 (25·2–38·6) 32·0 (25·5–40·5) 32·0 (25·6–39·3) 32·1 (25·9–44·7) 0·107
Sex
Women 464 (91%) 449 (88%) 447 (87%) 443 (87%) 0·061
Men 44 (9%) 62 (12%) 69 (13%) 69 (13%)  
Ethnicity
iTaukei 310 (61%) 309 (60%) 296 (57%) 305 (60%) 0·330
FID 196 (39%) 202 (40%) 215 (42%) 205 (40%) ··
Other 2 (<1%) 0 (0%) 5 (1%) 2 (<1%) ··
Residential location
Rural 239 (47%) 257 (50%) 216 (42%) 243 (47%) 0·054
Urban or peri-urban 269 (53%) 254 (50%) 300 (58%) 269 (53%) ··
Median number of children younger than 
5 years in household (IQR)
1 (1–2) 1 (1–2) 1 (1–2) (n=513) 1 (1–2) 0·545
Exposure to household cigarette smoke 276 (54%) 276 (54%) 269 (52%) 296 (58%) 0·323
Symptoms of URTI 106 (21%) 82 (16%) 84 (16%) 106 (21%) 0·064
Antibiotic use in previous fortnight† 38 (7%) 19 (4%) 11 (2%) 16 (3%) 0·0001
Poverty‡ 306 (71%) (n=433) 345 (68%) 280 (55%) (n=510) 258 (50%) <0·0001
Data are n (%), unless otherwise specified. In 2012, there was some missing data for poverty, likely due to perceived sensitivity when asking about income; this was rectified by 
additional field training in subsequent surveys. FID=Fijians of Indian descent. URTI=upper respiratory tract infection (includes any of the following: ear discharge, runny nose, and 
cough at time of survey). PCV10=received two or three doses of ten-valent pneumococcal conjugate vaccine before the survey; no 5–8-week-old infants or caregivers received 
this vaccine. *p values compare across years using chi-squared test for categorical data and Kruskal-Wallis test for continuous data. †As reported by parent or guardian. ‡Poverty 
defined as weekly family income below the basic needs poverty line (<FJ$175 per week).26
Table 1: Characteristics of study participants in annual cross-sectional pneumococcal carriage surveys in Fiji, by age group and year
For more on the Fiji 
demographic data see 
http://www.statsfiji.gov.fj/
See Online for appendix
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and Valelevu Health Centre, and surrounding com-
munities. Recruitment and carriage surveys were done in 
2012–15 during July–December, in the same villages 
and health centres each year (appendix). Approxi mately 
500 participants were enrolled each year from each of the 
following age groups: 5–8-week-old infants, 12–23-month-
old children, 2–6-year-old children, and their caregivers. 
We calculated sample size on the basis of an anticipated 
50% decrease in PCV10 serotype carriage prevalence from 
an estimated baseline prevalence of 16%, and increased 
size to 500 per group because the true baseline and effect 
sizes were unknown. Purposive quota sampling was 
undertaken, so that a representative sample of the Fiji 
population was included, with enrolment targets of 
60% iTaukei and 40% FID and approximately 50% of 
partici pants from rural areas. Inclusion criteria were 
appropriate age, axillary temperature lower than 37°C, and 
having lived in the community for at least 3 consecutive 
months.
Written informed consent was obtained (from parent or 
guardian for paediatric participants). This study was done 
according to the protocol approved by the Fiji National 
Health Research and Ethics Review Committee (201228) 
and the University of Melbourne Health Sciences Human 
Ethics SubCommittee (1238212).
Study procedures and laboratory analyses
Study staff recorded information on demographics and 
potential risk factors for pneumococcal carriage on a data 
collection form. PCV10 status was obtained from maternal 
and child health cards or the child’s health centre record, if 
the card was not available. Nasopharyngeal swabs were 
collected and stored according to WHO guidelines.22 
Detection of pneumococcus and H influenzae was done by 
real-time quantitative PCR (qPCR) targeting the lytA gene 
for pneumococcus and hpd gene for H influenzae.23,24 
Molecular serotyping of pneumococci by microarray was 
done as previously described in the literature (more details 
in the appendix).25
Statistical analysis
We did statistical analyses with GraphPad Prism 
(version 7.03) and Stata (versions 14.2 and 15.1). The 
χ² test was used to compare categorical data, and the 
Kruskal–Wallis test to compare continuous data, unless 
otherwise noted. Bacterial density data were log10 
transformed and reported as log10 genome equivalents per 
mL (log10 GE per mL). Because not all density data were 
normally distributed, we used non-parametric analysis 
methods.
We assessed carriage prevalence of overall pneumo cocci, 
PCV10 serotypes, and non-PCV10 serotypes for each study 
year. We calculated prevalence ratios by comparing 
each post-introduction year with 2012, the pre-PCV10 
introduction year. For each participant and age group, 
univariable log-binomial regression models were fitted to 
estimate unadjusted prevalence rate ratios of overall 
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Figure 1: Nasopharyngeal carriage prevalence per age group and year
Carriage prevalence of overall pneumococci (A), ten-valent pneumococcal conjugate vaccine (PCV10) serotype 
pneumococci (B), and non-PCV10 serotype pneumococci (C) in four different age groups in Fiji, in 2012–15. 
PCV10 was introduced in 2012 after our first carriage survey was done. Error bars depict 95% CI.
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pneumococcal carriage in association with participant 
characteristics. With use of variables considered associ-
ated with overall carriage (p<0·1), multivariable log-
binomial regression models were fitted to estimate the 
adjusted prevalence ratios of overall pneumococcal, 
PCV10 serotype, and non-PCV10 serotype carriage. The 
month of swab collection was also included in the 
adjusted models. Separate models were fitted for each 
age group. When log-binomial models did not converge, 
we used Poisson models with robust 95% CIs, with 
incidence ratios as a proxy for prevalence ratios.12 The 
comparison of log-binomial results with Poisson results 
where possible confirmed the comparability. Percent 
reductions in PCV10 carriage were quantified as 
(1–adjusted prevalence ratio) × 100.
To investigate the potential effects of PCV10 intro-
duction on pneumococcal density, we focused on the 
12–23-month-old age group, because we anti cipated that 
any vaccine-related effects primarily would be in 
the PCV10 age-eligible group. We used quantile (median) 
regression to analyse pneumococcal density by PCV10 
vaccination status for 12–23-month-old children, com-
bining data from all 4 years. To adjust for potential 
confounders, a multi variable quantile regression model 
included variables found to be associated with density by 
univariable analysis (p<0·1).
Role of the funding source
Fiji Health Sector Support Programme contributed to 
study conception and design. The funders had no role in 
data collection, analysis, or interpretation, or decision to 
publish. EMD had full access to study data and FMR 
had final responsibility for the decision to submit for 
publication.
Results
There were 8109 participants in the surveys, with 
characteristics shown in table 1. The ethnic distribution 
of participants was similar across surveys, with minor 
variations in residential location. A total of 43 participant 
samples were excluded from analysis because of in-
sufficient volume, sample loss, labelling errors, or other 
technical issues. In the 12–23 months age group, the 
percentage of participants who were PCV10 vacci nated 
increased from zero in 2012 and 11 (2%) in 2013, 
to 474 (95%) in 2014 and 498 (100%) in 2015. By contrast, 
for 2–6-year-olds, 116 (23%) participants were vaccinated 
in 2015 (table 1).
Figure 1 and appendix (p 3) show the carriage 
prevalence of overall pneumococci, PCV10 serotypes, 
and non-PCV10 serotypes, by age group and year. 
Table 2 shows the unadjusted and adjusted prevalence 
ratios for each post-PCV10 year compared with 2012. 
3 years after PCV10 introduction, reductions in PCV10 
serotype carriage were observed in the three paediatric 
groups (table 2). Because 116 (23%) of children aged 
2–6 years were PCV10 vaccinated in 2015, we did a post-
hoc subanalysis including only the unvaccinated children 
to investigate indirect effects specifically. The adjusted 
prevalence ratio of PCV10 serotype carriage for these 
2013 2014 2015
PR (95% CI) aPR* (95% CI) PR (95% CI) aPR* (95% CI) PR (95% CI) aPR* (95% CI)
All pneumococci
5–8 weeks† 0·78 (0·64–0·96) 0·89 (0·68–1·15) 0·52 (0·40–0·66) 0·69 (0·51–0·95) 1·17 (0·98–1·40) 1·29 (1·05–1·58)
12–23 months† 0·96 (0·84–1·09) 0·78 (0·68–0·90) 0·65 (0·55–0·76) 0·64 (0·54–0·76) 0·90 (0·79–1·03) 0·91 (0·79–1·05)
2–6 years† 0·87 (0·77–0·98) 0·85 (0·73–0·99) 0·63 (0·54–0·73) 0·69 (0·59–0·81) 0·82 (0·72–0·93) 0·90 (0·79–1·03)
Caregivers 1·26 (0·90–1·76) 1·23 (0·81–1·86) 0·63 (0·42–0·95) 0·68 (0·43–1·07) 0·75 (0·51–1·11) 0·82 (0·54–1·23)
PCV10 serotypes
5–8 weeks 0·62 (0·40–0·96) 0·44 (0·26–0·77) 0·36 (0·21–0·62) 0·34 (0·18–0·66) 0·61 (0·39–0·96) 0·56 (0·34–0·93)
12–23 months 0·84 (0·66–1·08) 0·63 (0·48–0·83) 0·36 (0·25–0·50) 0·37 (0·26–0·52) 0·33 (0·23–0·47) 0·34 (0·23–0·49)
2–6 years 0·68 (0·52–0·88) 0·56 (0·40–0·79) 0·35 (0·25–0·49) 0·35 (0·24–0·52) 0·42 (0·30–0·58) 0·47 (0·34–0·66)
Caregivers 1·41 (0·68–2·92) 1·24 (0·47–3·30) 0·65 (0·27–1·59) 0·76 (0·26–2·17) 0·33 (0·11–1·02) 0·43 (0·13–1·42)
Non-PCV10 serotypes
5–8 weeks† 0·85 (0·65–1·09) 1·16 (0·85–1·60) 0·58 (0·43–0·78) 0·92 (0·63–1·34) 1·46 (1·17–1·82) 1·72 (1·33–2·22)
12–23 months 1·15 (0·96–1·38) 1·09 (0·90–1·32) 0·86 (0·70–1·05) 0·91 (0·74–1·12) 1·27 (1·06–1·51) 1·28 (1·07–1·54)
2–6 years† 0·95 (0·81–1·11) 0·99 (0·82–1·20) 0·69 (0·58–0·83) 0·78 (0·65–0·95) 0·94 (0·80–1·10) 1·05 (0·89–1·23)
Caregivers 1·24 (0·83–1·83) 1·28 (0·80–2·06) 0·67 (0·42–1·07) 0·74 (0·45–1·23) 0·83 (0·53–1·28) 0·90 (0·57–1·43)
*Variables were adjusted for each age group. 5–8 weeks: ethnicity, two or more children younger than 5 years in the household (multiple under-5s), symptoms of upper 
respiratory tract infection (URTI), poverty, method of delivery, breastfeeding status, and month of swab collection. 12–23 months: ethnicity, residential location, multiple 
under-5s, URTI, poverty, and month of swab collection. 2–6 years: ethnicity, residential location, multiple under-5s, exposure to household cigarette smoke, URTI, poverty, 
and month of swab collection. Caregivers: ethnicity, sex, multiple under-5s, URTI, poverty, and month of swab collection. †Log-binomial regression model data did not 
converge, so a Poisson regression model was used to estimate adjusted prevalence ratios.
Table 2: Unadjusted (PR) and adjusted (aPR) carriage prevalence ratios for all pneumococci, ten-valent pneumococcal conjugate vaccine (PCV10) serotypes, 
and non-PCV10 serotypes compared with 2012
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unvaccinated children was 0·52 (95% CI 0·37–0·75, 
p=0·0004). In caregivers, there were no significant 
changes in carriage of PCV10 serotypes. Carriage of non-
PCV10 serotypes increased significantly in 5–8-week-olds 
and 12–23-month-olds in 2015.
Pneumococcal carriage by ethnicity is shown in 
figure 2 (see appendix, pp 4–6, for prevalence ratios). 
Pneumococcal carriage was higher in iTaukei participants 
than in FID participants. For paediatric groups, reduc-
tions in PCV10 serotype carriage in both ethnicities were 
consistent with overall results. In iTaukei caregivers, 
PCV10 serotype carriage was lower in 2015 than in 2012 
(appendix, p 4). No FID caregivers carried a PCV10 
serotype in 2012, therefore prevalence ratios were not 
calculated. An increase in carriage prevalence of non-
PCV10 serotypes in paediatric groups was observed only 
in iTaukei participants (figure 2).
We identified 3124 pneumococci, belonging to 
54 capsular serotypes plus seven genetic variants of non-
encapsulated pneumococci. 19·8% (95% CI 18·2–21·4) 
of pneumococcal-positive samples contained more than 
one serotype. The proportion of pneumococci that 
belonged to PCV10 serotypes declined significantly for 
all age groups in 2015, and for the 12–23 months and 
2–6 years groups in 2013, and 2014, compared with 
proportions in 2012 (appendix p 7). Serotype-specific 
carriage preva lences for paediatric groups are shown in 
figure 3 and the appendix (p 10). Carriage of several 
PCV10 serotypes was lower in 2015 than in 2012. Sero-
type 19A increased in 5–8-week-olds and 12–23-month-
olds, and serotype 35B increased in all three 
paediatric groups. We did not examine serotype-specific 
prevalences in caregivers because of the small values in 
this category. Changes in the serotype distribution of the 
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Figure 2: Nasopharyngeal carriage prevalence in the main Fiji ethnic groups
Nasopharyngeal carriage prevalence of overall pneumococci (A), ten-valent pneumococcal conjugate vaccine (PCV10) serotype pneumococci (B), and non-PCV10 serotype pneumococci (C) in Indigenous 
Fijians (iTaukei) and Fijians of Indian descent (FID) by year in four different age groups. Error bars depict 95% CI.
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Figure 3: Nasopharyngeal carriage prevalence of pneumococcal serotypes
Carriage prevalence of pneumococcal serotypes in Fijian children aged 5–8 weeks (A and B), 12–23 months (C and D), and 2–6 years (E and F). (A), (C), and (E) shown 
ten-valent pneumococcal conjugate vaccine (PCV10) serotypes. (B), (D), and (F) show vaccine-related serotypes 6A and 19A and any non-PCV10 serotypes that 
significantly increased in 2015, compared with 2012 (appendix p 10). *p<0·05 (exact p values shown in appendix, p 10).
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overall pneumococcal population are shown in the 
appendix (p 9).
Pneumococcal carriage density varied over time 
(figure 4). Density of PCV10 serotypes was lower in 2015 
(median 4·29 log10 GE per mL, IQR 3·35–5·10), than in 
2012 (4·98 log10 GE per mL, 4·23–5·67; p=0·0238 [Dunn’s 
post-test]). There were no differences in pneumo-
coccal carriage density between iTaukei children 
(median 5·05 log10 GE per mL, IQR 4·18–5·82) and FID 
children (4·97 log10 GE per mL, 4·11–5·72; p=0·531). The 
densities of overall pneumococci, PCV10 serotypes, and 
non-PCV10 serotypes were lower in PCV10-vaccinated 
12–23-month-old children than in unvaccinated children 
of the same age group (table 3). We found no significant 
differences in the density of individual serotypes.
We did not observe a significant difference in carriage 
prevalence of H influenzae in the 12–23 months age group 
between 2012 (39·6%, 95% CI 35·3–44·4) and 2015 
(40·0%, 35·6–44·4; p=0·84).
Discussion
To our knowledge, this study provides the first evidence of 
a population effect of PCV introduction in a low-income or 
middle-income country in the Asia-Pacific region. We 
observed direct and indirect effects on pneumococcal 
carriage, including reduced PCV10 serotype carriage in 
infants too young to be vaccinated. We expect that this 
reduction in vaccine-type carriage will translate to 
reductions in pneumococcal disease, as seen in settings 
with robust disease surveillance. Findings from a pros-
pective population-based study27 in the USA showed a 
39% decline in neonatal invasive pneumococcal disease 
and a 45% decline in invasive pneumococcal disease in the 
31–60 days age group after PCV7 introduction. Surveillance 
data28 from South Africa, covering pre-PCV, post-PCV7, 
and post-PCV13 periods showed that the incidence of 
invasive pneumococcal disease declined by 36% in infants 
younger than 10 weeks. In Israel,29 reductions in 
pneumococcal otitis media were observed in infants 
younger than 4 months after PCV13 introduction; because 
this age group received one vaccine dose or none, 
protection would largely be indirect.
2 years after PCV10 introduction, we observed a 
63% reduction in PCV10 serotype carriage in children 
aged 12–23 months similar to the 64% reduction in 
vaccine-eligible age groups observed in Kenya.12 Reductions 
in carriage of PCV10 serotypes in children aged 
12–23 months would be due to a combination of both 
direct and indirect effects.
We found no difference in carriage of H influenzae in 
vaccinated age groups pre-introduction and post-
introduction of PCV10, consistent with the results from a 
clinical trial in Finland.30 In 12–23-month-old children 
in Brazil,13 carriage of non-typeable H influenzae strains 
(NTHi) increased after PCV10 introduction. In Kenya,12 
NTHi carriage in children younger than 5 years declined 
in the post-PCV10 period, but the authors did not see 
evidence of an effect when comparing vaccinated with 
unvaccinated children. Together, these results suggest that 
PCV10 does not reduce carriage of H influenzae.
We observed potential indirect effects in Fiji, 3 years after 
PCV10 introduction in young, unvaccinated infants and 
older children, even in the absence of a catch-up campaign 
or a booster dose. Most Gavi-supported coun tries use a 
3 + 0 schedule for PCV, therefore our results are relevant 
for these settings. The degree of indirect effects is likely to 
be associated with the coverage achieved.31 The results of 
this study are consistent with a systematic review that 
found that carriage of vaccine serotypes declined in non-
target age groups after PCV introduction.11 Reductions in 
vaccine-type carriage occurred contemporaneously with 
reduc tions in vaccine-type invasive pneumococcal disease, 
supporting the usefulness of carriage as an alternative for 
disease surveillance to show the population effects of PCV.11
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Figure 4: Nasopharyngeal carriage density in children aged 12–23 months
Carriage density (log10 genome equivalents [GE] per mL) of overall pneumococci, 
ten-valent pneumococcal conjugate vaccine (PCV10) serotypes, and non-PCV10 
serotypes in children aged 12–23 months. Boxes show IQR with a central line 
denoting the median, and lines extend 1·5 times IQR past the quartiles. With 
Kruskal–Wallis test, we found that median density varied among years for overall 
pneumococci (p<0·0001), PCV10 serotypes (p=0·0002), and non-PCV10 serotypes 
(p=0·0040). Dunn’s post-test was used for p values (compared with 2012).
Number of 
carriers
Median 
density*
Adjusted coefficient† 
(95% CI)
p value Pseudo-R² 
value
Overall pneumococci
Unvaccinated 485 5·16 Reference 0·0004 0·031
PCV10-vaccinated 363 4·85 –0·39 (–0·61 to –0·18) ·· ··
PCV10 serotypes
Unvaccinated 207 5·16 Reference 0·0077 0·064
PCV10-vaccinated 72 4·45 –0·56 (–0·98 to –0·15) ·· ··
Non-PCV10 serotypes
Unvaccinated 331 5·03 Reference 0·0334 0·018
PCV10-vaccinated 312 4·86 –0·29 (–0·57 to –0·02) ·· ··
Data are from all four years combined. PCV10-vaccinated=received one or more doses of PCV10 vaccine. *Density reported 
in log10 genome equivalents per mL. †Coefficient is the difference in medians as determined by quantile regression, adjusted 
for upper respiratory tract infection symptoms, poverty, and two or more children younger than 5 years in the household.
Table 3: Quantile (median) regression analysis of pneumococcal density in ten-valent pneumococcal 
conjugate vaccine (PCV10) vaccinated and unvaccinated children aged 12–23 months who were 
pneumococcal carriers (n=848)
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In this study, we found evidence of indirect effects in 
caregivers, but only in iTaukei individuals, probably due to 
the low baseline carriage of PCV10 serotypes in 
FID individuals. Similarly, a non-significant decline in 
PCV13 serotype carriage was reported in adult Native 
Americans,32 which was attributed to a low baseline 
carriage (2%).
Pneumococcal carriage rates are consistently higher in 
iTaukei than in FID individuals, as observed in this study 
and in previous studies.21,33 After PCV10 introduction, 
carriage of PCV10 serotypes declined in both ethnic 
groups. However, serotype replacement in carriage 
occurred in iTaukei children and infants only, possibly 
because of higher baseline carriage of non-PCV10 
serotypes. Invasive pneumococcal disease surveillance is 
ongoing, because serotype replacement in carriage might 
become more prominent and lead to serotype replace ment 
in disease. Generally, PCV use decreases—but does not 
eliminate—disparity in invasive pneumococcal disease 
rates among different ethnic populations living in the 
same area.34
In many settings, serotype 19A was the primary 
replacement serotype after PCV7 introduction and was 
associated with increases in invasive pneumococcal 
disease.35 In Fiji, carriage of 19A increased in young 
children. However, this increase was small and similar in 
magnitude to several other non-PCV10 serotypes. In the 
PCV10 studies in Brazil13 and Iceland,14 carriage of 
19A did not change after PCV10 introduction. In Kenya, 
5 years after PCV10 introduction, 19A carriage prevalence 
had increased among children younger than 5 years.36 
Consistent with other studies,12–14,30 we saw no difference 
in carriage of 6A indicative of a cross-protective effect of 
PCV10.
The laboratory methods used in this study enabled 
quantitative detection of multiple serotypes within the 
same sample, a common occurrence in Fiji. Future studies 
might consider if and how multiple serotype carriage 
influences vaccine effect, and how results compare with 
those obtained with traditional methods.
The density of both PCV10 and non-PCV10 serotypes 
was lower in vaccinated children than in unvaccinated 
children, although we had hypothesised that vaccination 
would primarily affect PCV10 serotypes. Because most 
samples from unvaccinated children were from the early 
PCV10 introduction period (2012–13), and samples from 
vaccinated children from the later PCV10 period (2014–15), 
differences in density might be due to fluctuations in 
other unmeasured confounders rather than related to 
PCV10. In a study37 done with semi-quantitative methods, 
Dagan and colleagues found no difference in the density 
of the six additional serotypes included in PCV13 when 
comparing densities in children who received PCV7 with 
those in children vaccinated with PCV13.
In settings such as Fiji, carriage surveys are a practical 
way of assessing the effect of PCV introduction. A 
reduction in vaccine serotype carriage in the community is 
likely to translate to a reduction in vaccine-type 
pneumococcal disease. A limitation of any observational 
study on this topic is that it is difficult to distinguish 
vaccine effects from secular trends. Pneumococcal carriage 
prevalence in 2014 was low across all age groups, despite 
each annual survey being done with the same study 
methods and procedures. The decline in PCV10 serotypes 
might be associated with high vaccine coverage. However, 
this does not explain the decline in non-PCV10 serotypes, 
which might be related to unknown, and unmeasured, 
confounders. In 2015, a local influenza outbreak38 coincided 
with the carriage survey, which might have affected 
pneumococcal carriage that year. Such examples highlight 
the complexity of trend analyses. We did one carriage 
survey before PCV10 introduction, whereas multiple years 
of pre-PCV data would provide a more robust baseline.
PCV10 coverage in study participants was very high and, 
although consistent with national coverage rates (89% for 
the third dose of PCV10 in 2015), it might not be 
representative of remote areas of Fiji.39 Study participants 
could belong to the same household, but our analyses did 
not account for this lack of independence. Older children 
and adolescents were not surveyed and might represent 
a reservoir for vaccine-serotype carriage after PCV 
introduction.40
In conclusion, we have shown that the carriage of 
PCV10 serotypes in both vaccinated and unvaccinated 
individuals declined after PCV10 introduction in Fiji. 
Importantly, indirect effects were observed in infants too 
young to be vaccinated as well as older age groups who 
did not receive the vaccine. Serotype replacement in 
carriage was beginning to emerge 3 years after PCV10 
introduction and occurred solely in iTaukei children. We 
found no effect of PCV10 introduction on carriage of 
H influenzae. Monitoring of changes in pneumococcal 
carriage continues to be a valuable way to identify 
population effects after PCV10 introduction.
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